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Background: Over 30% of individuals use natural health products (NHPs) for osteoarthritis-related pain. The Deficit
Model for the Public Understanding of Science suggests that if individuals are given more information (especially
about scientific evidence) they will make better health-related decisions. In contrast, the Contextual Model argues
that scientific evidence is one of many factors that explain how consumers make health-related decisions. The
primary objective was to investigate how the level of scientific evidence supporting the efficacy of NHPs impacts
consumer decision-making in the self-selection of NHPs by individuals with osteoarthritis.
Methods: The means-end chain approach to product evaluation was used to compare laddering interviews with
two groups of community-dwelling Canadian seniors who had used NHPs to treat their osteoarthritis. Group 1
(n=13) had used only NHPs (glucosamine and/or chondroitin) with “high” scientific evidence of efficacy. Group 2
(n=12) had used NHPs (methylsulfonylmethane (MSM) and/or bromelain) with little or no scientific evidence
supporting efficacy. Content analysis and generation of hierarchical value maps facilitated the identification of
similarities and differences between the two groups.
Results: The dominant decision-making chains for participants in the two scientific evidence categories were
similar. Scientific evidence was an important decision-making factor but not as important as the advice from health
care providers, friends and family. Most participants learned about scientific evidence via indirect sources from
health care providers and the media.
Conclusions: The Contextual Model of the public understanding of science helps to explain why our participants
believed scientific evidence is not the most important factor in their decision to use NHPs to help manage their
osteoarthritis.
Keywords: Natural health products, Decision-making, Means ends chain analysis, OsteoarthritisBackground
Natural health products (NHPs) are defined in Canada
as products made from ingredients found in nature sold
over-the-counter for medical purposes [1] including
herbal medicines, vitamins and minerals. It is an estimated
3 billion dollar industry annually in North America [2].
Just over 70% of Canadians reported ever using a NHP as
of 2005 and 38% reported the daily use of NHPs [3].* Correspondence: heather.boon@utoronto.ca
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reproduction in any medium, provided the orSimilar statistics are reported for complementary and
alternative medicine (CAM [1]) use throughout the
Western world – with approximately 40% of individuals
currently using CAM, and 70% reporting past use in
Europe, Australia, and the United States [4,5].
Osteoarthritis (OA) is the most common form of
arthritis, affecting about 18% of females and 10% of
males over the age of 60 years worldwide. OA is a condi-
tion responsible for significant chronic disability as a
result of joint degeneration and reduction in mobility.
Approximately 60% of seniors with OA report using. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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30-45% report using NHPs [6,7]. The widespread self-
management of OA leads one to question how con-
sumers choose which products to purchase.
There are conflicting studies regarding the role scien-
tific evidence plays in influencing consumer choices
[8,9]. Recommendations of trusted individuals such as
health care providers (e.g., pharmacist, doctors), and
friends and family appear to play an important role in
non-prescription decision-making [10]. Yet previous
studies of consumer decision-making related to CAM
have suggested that individuals review and prioritize
scientific evidence as a decision-making factor [11-13].
Additionally, lack of scientific evidence or evidence of
ineffectiveness has been reported to sway consumers
away from using CAM therapies [14,15]. Thus it remains
unclear how scientific evidence fits into consumers’
decisions about NHPs.
Much consumer education focuses on giving people
“the evidence” about the safety and efficacy of various
treatment modalities, assuming that armed with this
information they will make the “right choice”. This
view is consistent with the Deficit Model for the Public
Understanding of Science [16]. Underlying this model is
the assumption that the public trusts scientific experts,
institutions, and perceives that scientific information is
useful and relevant to their decision-making process [16].
Another assumption is that the assimilation of scientific
knowledge into the decision-making process is directly
correlated to the amount of scientific knowledge an indi-
vidual possesses [17,18]. The Deficit Model has been
criticized for not providing adequate explanations for
those individuals who have the scientific information
and still choose not to use it in their decision-making
process. According to the Deficit Model, the public’s
doubts or concerns about scientific progress or innovation
are due to misunderstanding or ignorance about the sci-
ence that underlies it. While the Deficit Model as
described here is somewhat simplified to enhance the
clarity of this argument, it has been shown to underlie
many of the public education campaigns related to
health-related technology and treatments [17].
The Contextual Model was developed as a critique of
the Deficit Model in an attempt to explain why some
individuals make “unscientific” choices despite having
scientific knowledge. McKechnie, a proponent of the
Contextual Model writes: “scientific expertise is identi-
fied, experienced, and responded to in terms of the insti-
tutional, cultural, and social dimensions in which it is
always inevitably embedded” [16]. Contrary to the Deficit
Model, the Contextual Model cautions that trust in
authority should not be assumed [19]. Therefore, even if
“scientific” information is being conveyed by experts, the
public needs to first be convinced that understandingscientific information is important [20], or else attempts
to educate the public about the science are counter-
productive.
The purpose of this paper is to explore how consu-
mers use scientific evidence when choosing NHPs to
manage their OA. The findings are discussed in the con-
text of the Deficit and Contextual Models for the Public
Understanding of Science.
Methods
We used the means-end chain (MEC) approach to
understand osteoarthritis-related NHP self-medication
decisions [21-23]. The MEC approach, primarily used in
marketing research, is designed to help consumers re-
construct and verbalize what may have become largely
routine product evaluation processes [24,25]. Its asso-
ciated laddering interviewing technique enables eliciting
how consumers link product attributes with their values
and beliefs via the perceived consequences of the attri-
butes to obtain cognitive maps of production evaluation
and choice processes [22]. This project received approval
from the Office of Research Ethics at the University of
Toronto.
Participants
Stratified convenience sampling and snow-ball sampling
strategies were used to recruit 25 participants through
seniors activity centres, community organizations, news-
papers, magazines and an online community (craigslist).
English speaking adults with a self-reported diagnosis of
osteoarthritis of any joint for at least the last three
months who had self-medicated with at least one NHP
from the following list: glucosamine, chondroitin, MSM
or bromelain in the last year, were invited to participate.
These four products were selected because of their rela-
tively common use and ease of access in the greater
Toronto area, as well as to allow comparison of pro-
ducts with a relatively high level of scientific evidence
of efficacy and products with a relatively low level of
scientific evidence of efficacy. The aim of recruitment
was to have two groups: one composed of participants
who reported only using NHPs with high levels of sci-
entific evidence (levels A or B as defined by the Natural
Standard database [26]; in our case glucosamine and
chondroitin) and one composed of individuals only
using NHPs with little or no scientific evidence (level C
or lower as defined by Natural Standard [26]; in our
case bromelain and MSM). However, it was not pos-
sible to recruit participants who had never tried glu-
cosamine or chondroitin due to the popularity of these
NHPs in North America. Thus if a participant reported
using any product lacking levels A or B evidence sup-
port (e.g., bromelain and MSM which have level C or
lower evidence support), they were assigned to the
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vious professional health care training, employment
with an NHP manufacturer or market research com-
pany, patients of any of the study investigators or over
the age of 80 were excluded. The upper limit of age 80
was set based on our team’s previous experience with
the laddering interview which can last up to 2 hours
and be quite mentally and physically challenging, particu-
larly for more elderly individuals. The sample was
selected to include both men and women with a range of
ages, levels of education and income. Written informed
consent was obtained from all participants prior to each
interview.Data collection
Face-to-face semi-structured interviews using the ladder-
ing process and lasting 60 to 90 minutes were con-
ducted. Interviews were audio-recorded and transcribed
verbatim. There were four general steps to the interview:
1) general questions inquiring about how participants
found out about their NHPs; 2) the laddering interview,
as described in detail below; 3) a brief semi-structured
interview about participants’ views on scientific evidence;
and, 4) socio-economic and demographic information
collected via a standardized questionnaire. Each partici-
pant received a $50 gift card for participating in the study.
In the laddering section of the interview, partici-
pants were first asked to state what they like and dis-
like about the products which they have used in the
past six months. Next, participants were asked about
the remaining products they had heard of, but not
used to find out why they did not use them. Based
on these responses, the interviewer compiled a list of
all specific product attributes salient to that individual
participant.
Each product attribute formed the starting point of a
ladder, linking the product attribute with its associated
consequence(s) and the underlying personal value(s).
Variations of the probing question “Why is that important
to you?” were used to encourage participants to think
more deeply about the meaning of each step, leading to
increasingly abstract concepts being elicited [22,24,25].
A ladder was concluded when the respondent had
reached the most abstract level of terminal values or
was not able to answer the probing question.Data analysis
Analysis of laddering data proceeded in three steps.
First, three coders independently identified attributes,
consequences and values and the links between them in
each respondent’s transcript. Second, for each partici-
pant the coded data were entered as ladders into the
MECanalyst Plus [24] software, which summarizes theindividual participant data in the so-called implication
matrix that documents the number of links between all
attributes, consequences and values that were identified
in the first step. Third, the software was run to generate
a graphic representation of the data referred to as hier-
archical value maps (HVM) (See Figures 1 and 2). HVMs
illustrate the links between individual concepts. The
strength of a link is measured by the number of respon-
dents that made that link in a laddering interview. The
fundamental assumption of the MEC approach is that
the strength of a link indicates how readily a more
abstract concept (e.g., a value) is activated by a perceived
consequence or attribute [22]. Links mentioned by very
few participants are assumed to either represent idiosyn-
cratic participant responses or play a minor role in
product evaluation and decision-making [22]. A cut off
defines a minimum number of mentions that a link must
have to appear in the HVM. Increasing the cut off
reduces the information content of the HVM – it is
100% at cut off one – but also enhances its tractability.
The chosen cut off for the high and low scientific evi-
dence HVMs was three which retained an acceptable
54% and 62% of the links, respectively.
Constant comparative content analysis was used to
code discussions of scientific evidence and other sources
of information throughout the interviews. Coding was
completed independently by three investigators, with
regular meetings scheduled every two to three interviews
in order to ensure consensus between investigators.
NVivo software was used to facilitate the content
analysis [27].Results
Overview of participants’ demographic characteristics
Of the 25 participants, 13 had only used NHPs in the
high [2] scientific evidence category and 12 had used
NHPs in the low [3] scientific evidence category. Overall,
no statistically significant differences were found between
participants in the high and low scientific evidence cat-
egories with respect to gender, age, ethnicity, education
level, net household income, presence of extended health
insurance, duration of using NHPs, perceived importance
of scientific evidence, overall perceptions of health, or
pain severity (See Table 1).
When reading the HVMs in Figures 1 and 2, the
numbers inside the boxes represent the percentage of
all participants who mentioned the concept. The thick-
ness of the lines connecting each of the concepts
represents the strength of each linkage. The domin-
ant chain that includes scientific evidence, described
in the section below, captures the concepts used for
product evaluation which relate to our central research
question.
Figure 1 High Scientific Evidence Group Hierarchical Value Map.
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dence groups described deciding to use NHPs because
of perceptions about the scientific evidence for the efficacy
or safety of the product, and endorsements by trusted
individuals. Participants described being more likely to
take NHPs when they expected fewer or no side effects.
After taking the NHPs, participants reported experiencing
reduction in pain, being able to perform more of their
daily activities, and ultimately leading lives of improved
quality and independence. An exploration of the salient
0product attributes, consequences, and values found in
the dominant chain that includes scientific evidence is
provided below.Perceptions of scientific evidence
Participants expressed a general understanding that sci-
entific evidence in our study was defined as published
research studies using the scientific method. Both “high”
and “low” participants endorsed scientific evidence as
playing a role in their decision making. Scientific evi-
dence was rated as important in their selection of NHPs
(mean 8/10, scale 0= not important to10 = important)
with no significant differences between the groups (See
Table 1). Scientific evidence as a product attribute was
discussed by 58% of the low scientific evidence group
and 46% of those in the high scientific evidence group as
a factor related to their product choice(s). Even though
Figure 2 Low Scientific Evidence Hierarchical Value Map.
Tsui et al. BMC Complementary and Alternative Medicine 2012, 12:198 Page 5 of 10
http://www.biomedcentral.com/1472-6882/12/198our participants appeared to understand the scientific
method, and frequently linked the presence of scientific
evidence with effectiveness such as a reduction in pain,
there was no mention of strength of scientific evidence
improving the probability of benefit. Instead, our partici-
pants frequently associated presence of scientific evi-
dence with a decreased frequency of side effects.
During the semi-structured portion of the interview,
most participants reported hearing about scientific evi-
dence from an indirect source such as a friend or family
member, a health care provider, media source or the
internet; as opposed to directly seeking out scientific
research studies to read. Scientific evidence was not
described by most participants as a necessary condition
for choosing a specific NHP to treat their OA. It was
reported to be just “another nail in the coffin” and tobe useful if it confirmed “what the other people said.”
(High Evidence, M1).
Overall, our participants appeared to have a superficial
understanding of scientific evidence. For example, none
of them appeared to understand the significance of the
evidence-based medicine’s (EBM’s) hierarchy of scientific
evidence [28]. The EBM hierarchy is generally accepted
in the research and clinical communities, and was
adopted by the Natural Standard Database to determine
levels of scientific evidence supporting NHPs.
Endorsements of trusted individuals
One of the most important product attributes influencing
a participant’s selection of an NHP was the endorsement
by someone the individual trusted. Friends and family
were usually the initial, and often the most important,
Table 1 Participant demographics and other characteristics
Item Everyone (N = 25) High (N = 13) Low (N = 12) p-value
Gender 19 (76) 10 (77) 9 (75) 1a
Female, N (%)
Mean Age in years (range) 58.8 (42–78) 55.08 (42–78) 62.92 (43–78) 0.100 b
Ethnicity, N (%) 0.422b
North American 10 (40) 6 (46) 4 (40)
European 13 (52) 5 (38) 8 (62)
Other 6 (24) 4 (67) 2 (33)
At least some college as highest education, N (%) 15 (60) 9 (69) 6 (50) 0.428a
Annual household net income less than $50,000 dN (%) 14 (56) 7 (54) 7 (58) 1a
Have Extended health insurance, N (%) 12 (48) 6 (46) 6 (50) 1a
Use of NHPs to treat Osteoarthritis longer than 6 months N (%) 21 (84) 9 (69) 12 (100) 0.096 a
Mean importance of scientific evidence rating
(0 = unimportant, 10 = very important) (standard deviation)
8 (2.3) 8 (2.6) 7.9 (2.1) 0.931c
Mean overall health rating (0 = worst, 10 = best) (standard deviation) 7.2 (1.2) 7.0 (1) 7.5 (1.4) 0.322 c
Mean pain scale visual analogue scale, 0 = worst, 10 = best
(standard deviation)
6.7 (1.8) 6.2 (2.0) 6.9 (1.6) 0.328c
Joints affected dN (%)
Upper extremity 4 (21) 1 (10) 3 (33) 0.270b
Lower extremity 12 (63) 8 (80) 4 (44)
Other 3 (16) 1 (10) 2 (22)
Total joints affected 19 (100) 10 (100) 9 (100)
Recruitment locationb – N (%)
Senior community centre 5 (20) 1 (20) 4 (80) 0.2505 b
Online community website 17 (68) 11 (65) 6 (35)
Health food store 2 (8) 1 (50) 1 (50)
Natural Health Products Used – N (%)
Glucosamine 25 (100) 13 (100) 12 (100)
Chondroitine 18 (72) 8 (62) 10 (83)
MSM 0 (0) 0 (0) 10 (83)
Bromelain 4 (16) 0 (0) 4 (33)
Caption: a: Fisher test, b: Chi-square test, c: unpaired t-test; d: four participants did not indicate their income; e: chondroitin products were almost always in
combination with glucosamine. All tests were performed using Prism GraphPad version 5.0 for Windows. Participants could indicate more than one anatomical
joint; five participants did not indicate an affected anatomical joint.
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evidence of efficacy:
Like I said, if my friend didn’t tell me that it worked,
I wouldn’t know [. . .] I didn’t do a search, no. I just
took my friend’s word for it.
(High Evidence, M3).
If my son says take it, I’ll trust him.
(Low Evidence, F5).
Endorsement of a product by a health care provider
was also an important source of information. The typesof health care providers consulted (CAM vs. conven-
tional) did not significantly differ between the two
groups of participants. Trust also appeared to be a key
element in participants’ interactions with their health
care providers:
I trust what he [my family doctor] says to me. I don’t
think I’ve ever questioned anything he ever says to
me.
(High Evidence, M1).
Participants who discussed their physicians quoting
scientific evidence usually recalled the information from
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efficacy of a NHP:
And [the doctor] said, well it’s not a product that
really works. The doctor, he told me I could take a
placebo pill, it would be the same way [. . .] he didn’t
say it was bad [or] don’t take it, it’s going to do
negative things. He just said, it has no value.
(Low Evidence, F2).
The advice of health care providers appeared to be
playing slightly different roles in the decision making
process for participants in the high and low scientific
evidence groups. Participants in the high scientific evi-
dence group related the endorsement of a health care
provider to both the product’s efficacy (i.e. it decreased
their pain) and how it worked (its mechanism of action).
In contrast, participants in the low evidence category
linked the knowledge that a product was endorsed by a
health care provider with the perceived lack of (or fewer)
side effects but did not identify a strong link to mechan-
ism of action.
Participants in both scientific evidence categories
talked about the NHP’s pain reduction ability as being
key in allowing participants to perform their activities of
daily living, feeling healthier physically, and emotionally,
and being able to participate in social activities. Two key
linkages mentioned by participants in the high scientific
evidence category, but not mentioned by participants in
the low scientific evidence category, were the import-
ance of social activity and being in control of one’s
health, both consequences which the participants linked
with an improvement in quality of life.
Overall, two values (striving for an improved quality of
life and maintaining independence) appear to be under-
pinning the decision to use NHPs for participants in
both scientific evidence groups. Most participants in
both groups described that experiencing less pain ultim-
ately led to improved quality of life. “Quality of life” was
defined by the participants as attaining more happiness,
meaning, or purpose to live. Similarly, enabling
improved activities of daily living led to greater levels of
independence in both scientific evidence groups. In
addition, more participants in the low scientific evidence
group tended to associate the natural source of NHPs
with being able to adopt a “natural way of living.” Only
one participant in the low scientific evidence group
made such a link (which means it is not present in the
HVM because it was below the cut-off of three).
Discussion
According to the Deficit Model participants who were in
the high scientific group (i.e., who only used products
supported by scientific evidence) should have reportedmore exposure to, and place more value on, scientific
evidence than those purchasing products without scien-
tific evidence of efficacy. This was not what we found.
Participants in both groups appeared to have a very gen-
eral understanding of the scientific method and identified
scientific evidence as a factor in their decision-making.
Upon detailed questioning in the semi-structured inter-
views, scientific evidence was not of primary importance
to participants in either group. Further, participants who
cited scientific evidence as a product attribute frequently
associated the scientific evidence supporting an NHP
with a reduction in side effects instead of acknowledging
the greater probability of benefit of NHPs with higher
levels of scientific evidence according to the EBM hier-
archies of evidence [28]. This suggests that a reduction in
side effects could be more personally meaningfully to
many CAM users, regardless of probability of efficacy,
a finding reported in previous CAM decision-making
studies [11,13,29].
We believe that the Contextual model is helpful at
explaining our findings since it recognizes that it is not
simply an understanding of scientific facts that it is im-
portant when people make decisions, but rather how
that information fits into their everyday experiences,
concerns and values [17]. The Contextual Model can
also explain the role of trust in individuals with authority
(such as health care providers), as well as the profound
influence of endorsements from friends and family to an
individual’s decision-making process.
Our participants identified scientific evidence as a prod-
uct attribute impacting their selection of NHPs, which is
consistent with previous qualitative study findings where
patients with arthritis [12], breast cancer [13-15], and
prostate cancer [30,31] reported using scientific evidence
as an information source guiding their decision making
process when selecting CAM treatment therapies. While
participants in this study identified scientific evidence as
important, more detailed interviewing revealed that sci-
entific evidence played a relatively unimportant role in
decision-making compared to other factors such as per-
sonal advice. The reason our findings appear to differ
from previous CAM decision-making studies could be
our in-depth semi-structured interview questions which
probed participants’ views of scientific evidence and
allowed us to directly explore the relative importance of
scientific evidence compared to other factors.
Similar to other CAM decision-making studies in
patients diagnosed with cancer, most of our participants
did not report going to the scientific research to read it
first-hand, instead, they considered indirect sources such
as internet searches, newspaper-articles, or health care
providers’ endorsements sources of scientific evidence
[14,15,32,33]. Proponents of the Contextual model sug-
gest that individuals will choose indirect forms of
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vance [16], and not because there is a lack of access to
direct scientific evidence. This is something which could
be explored more in future studies.
The MEC approach is based on an assumption that
product selection is ultimately driven by attempts to
fulfill an end or core value. Three core values emerged
in our findings – desiring a natural way of living, quality
of life, and independence. The most distinct value
which appears to characterize participants who selected
products without scientific evidence support was the
desire for a “natural way of living”. This is consistent
with previous research which suggests that individuals
who use CAM appear to value a holistic way of living
and the connection between the mind and body
[12,13,15], not shared by those who only use conven-
tional medicine [12]. A preference for things natural has
also been found to be important in food choices [34-37].
A previous study by our team found that in consumers
selecting sleep aids, individuals’ product selection process
included making different tradeoffs between product attri-
butes (e.g., naturalness) and perceived consequences
(e.g., efficacy and side effects). These tradeoffs were
done in an effort to maximize values such as overall
quality of life [11]. Future research should focus on how
and when these tradeoffs are made by consumers as well
as how positioning consumer communication in person-
ally meaningful contexts impacts them.
There are some limitations to this study. For example,
we had a relatively small sample size (n =25). Nonethe-
less our sample (over 75% female participants, with a
mean age of over 58 years, of North American heritage,
consisting of fairly well educated (>60% with college
education) individuals with over half earning more than
$50,000) has similar demographics to the target group –
individuals with arthritis who choose to use NHPs or
CAM therapies in general [7,12,38]. This suggests that
our results capture the decision-making process of our
target population. The participants who used NHPs with
low levels of scientific evidence support could have
also used NHPs with high levels of scientific evidence
support, which could explain why there were relatively
few differences between the two groups. However, our
decision to allocate participants into groups based on
their revealed preferences (i.e., based on the NHPs
they actually used), rather than based on their stated
preferences, enhances the validity of our findings. Most
of our participants stated that scientific evidence of
efficacy was important in their decision-making; yet their
product choices suggest this is not always the case.
Lastly, we did not test for scientific literacy; however,
there was no significant difference between the education
levels of both groups which is a proxy for scientific
literacy.Conclusion
In conclusion, this study found that scientific evidence
does play a role in consumer decision-making about
NHPs; however, it is less important than the advice pro-
vided by health care providers, friends and family. Very
few participants used direct scientific evidence sources
in the decision-making process; most acquired know-
ledge of scientific evidence through indirect sources
such as health care providers or the media, highlighting
the responsibility of these groups to critically assess the
quality and validity of scientific evidence since consu-
mers/patients rely on them for accurate information.
The Contextual Model of the Public Understanding of
Science helps to explain why scientific evidence is not
the most important decision-making factor because it
helps us understand how perceived personal relevance is
used to filter all information relevant to these types of
decisions. Future research should focus on the content of
the interactions between patients and heath care provi-
ders regarding scientific evidence, the perceived import-
ance of different indirect sources of scientific evidence,
and knowledge translation strategies to more effectively
convey scientific evidence to the lay audience in ways
they find personally meaningful.
End notes
1. Products and therapies generally defined as not
being part of the dominant health care system.
2. Evidence level A or B only. Level A evidence is
strong scientific evidence, where level B is good scientific
evidence, both according to the Natural Standard
Database.
3. Evidence level C or traditional/insufficient evidence.
Level C evidence is unclear or conflicting scientific evi-
dence according to the Natural Standard Database.
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